• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用示踪方法对帕金森病患病率的研究。

Studies on the prevalence of paralysis agitans by tracer methodology.

作者信息

de Pedro Cuesta J

出版信息

Acta Neurol Scand Suppl. 1987;112:1-106.

PMID:3303809
Abstract

The present study was motivated by the methodological issues revealed by a review of previous studies on Paralysis Agitans (PA) epidemiology. The study was given the following aims: To identify an easy available, inexpensive marker of PA frequency in populations; to develop, standardize and validate a model for measurement of PA prevalence by using that tracer; to study the geographical distribution of PA in Sweden, and to use the model in environmental risk analysis (ERA) for PA. Information on diagnoses and anti-parkinsonian drugs (APD) utilization from Swedish registers was analyzed, in order to select the group of APD which would best fulfill the prerequisites of specificity and preference of choice, and combined with prevalence data from direct surveys. Levodopa drugs were found to be the most suitable tracer for PA prevalence. A mathematical model was formulated to generate annual estimates for average age specific prevalences from total sales of levodopa, age specific population and figures for infant mortality rates. The following was required in order for the model to yield accurate estimates: high quality of the information to be used, good availability of levodopa drugs, a minimal size of the studied population of 100,000, an IMR lower than 28.8 per 1000 and that levodopa diffusion had reached the late adoption phase. Underdiagnosis was found to constitute an important cause of bias in classical surveys. Standardization for age and health services effectiveness by using infant mortality rates was shown to improve comparability of prevalence figures. The model was validated and showed internal consistency for age specific data on levodopa sales and on prevalence from Sweden and six Chinese towns, respectively. Estimates for prevalence for Iceland and Sardinia fitted historical data from direct surveys. The results of the ERA study showed that a high latitude and a low population density in 1900-20 were correlated with an increase in PA prevalence as measured by surveys or estimated by the use of the tracer method. Further analysis indicated that several so-called risk factors or concomitant diseases are associated with low population density. The geographical distribution of standardized PA prevalences in Swedish counties was studied for the period 1977-84. The findings were in accordance with the figures expected from the natural characteristics of the disease as determined by latitude and population density except in the county of Gävleborg which showed a significantly higher, and continuously increasing prevalence.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

本研究的动机源于对帕金森病(PA)流行病学先前研究回顾所揭示的方法学问题。该研究设定了以下目标:确定一种在人群中易于获取且成本低廉的PA频率标志物;开发、标准化并验证一种使用该标志物测量PA患病率的模型;研究PA在瑞典的地理分布,并将该模型用于PA的环境风险分析(ERA)。分析了瑞典登记册中关于诊断和抗帕金森病药物(APD)使用的信息,以便选择最能满足特异性和选择偏好前提条件的APD组,并结合直接调查的患病率数据。发现左旋多巴药物是PA患病率最合适的标志物。构建了一个数学模型,根据左旋多巴的总销售额、特定年龄人口以及婴儿死亡率数据来生成特定年龄平均患病率的年度估计值。为使该模型产生准确估计值,需要满足以下条件:所使用信息的高质量、左旋多巴药物的良好可及性、研究人群最小规模为10万、婴儿死亡率低于每1000人28.8例,以及左旋多巴的传播已进入后期采用阶段。发现漏诊是经典调查中偏差的一个重要原因。通过使用婴儿死亡率对年龄和卫生服务效果进行标准化,可提高患病率数据的可比性。该模型经过验证,分别显示了瑞典和中国六个城镇关于左旋多巴销售的特定年龄数据以及患病率数据的内部一致性。冰岛和撒丁岛的患病率估计值与直接调查的历史数据相符。ERA研究结果表明,1900 - 20年期间的高纬度和低人口密度与通过调查测量或使用示踪法估计的PA患病率增加相关。进一步分析表明,一些所谓的风险因素或伴随疾病与低人口密度有关。研究了1977 - 1984年期间瑞典各县标准化PA患病率的地理分布。除了耶夫勒堡县显示出明显更高且持续上升的患病率外,研究结果与根据纬度和人口密度确定的疾病自然特征所预期的数字相符。(摘要截断于400字)

相似文献

1
Studies on the prevalence of paralysis agitans by tracer methodology.用示踪方法对帕金森病患病率的研究。
Acta Neurol Scand Suppl. 1987;112:1-106.
2
Tracers for paralysis agitans in epidemiological research. III. Refinement of the model for estimation of the prevalence of the disease.震颤麻痹流行病学研究中的追踪指标。III. 疾病患病率估计模型的完善
Neuroepidemiology. 1985;4(3):161-75. doi: 10.1159/000110227.
3
Tracers for paralysis agitans in epidemiological research. IV. Trends in national drug policy and measurement of the prevalence of the disease in Sweden.流行病学研究中帕金森病的追踪指标。IV. 瑞典国家药物政策趋势及疾病患病率测量
Neuroepidemiology. 1985;4(3):176-85. doi: 10.1159/000110228.
4
Tracers for paralysis agitans in epidemiological research. V. Prevalence of the disease in Swedish counties.震颤麻痹的流行病学研究追踪指标。五、瑞典各郡该疾病的患病率。
Neuroepidemiology. 1986;5(4):207-19. doi: 10.1159/000110830.
5
[Meta-analysis of the Italian studies on short-term effects of air pollution].[意大利关于空气污染短期影响研究的荟萃分析]
Epidemiol Prev. 2001 Mar-Apr;25(2 Suppl):1-71.
6
High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology? Europarkinson Preparatory Activity Research Group.冰岛出生队列中左旋多巴在特定时间聚集期的高剂量使用。帕金森病病因的一种残留现象?欧洲帕金森病前期活动研究小组
Acta Neurol Scand. 1995 Feb;91(2):79-88. doi: 10.1111/j.1600-0404.1995.tb00412.x.
7
Multicity study of air pollution and mortality in Latin America (the ESCALA study).拉丁美洲空气污染与死亡率的多城市研究(ESCALA研究)。
Res Rep Health Eff Inst. 2012 Oct(171):5-86.
8
Epidemiological assessment of levodopa use by populations.人群使用左旋多巴的流行病学评估。
Acta Neurol Scand. 1991 May;83(5):328-35. doi: 10.1111/j.1600-0404.1991.tb04711.x.
9
Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study.丹麦抗帕金森病药物的使用:一项全国性药物流行病学研究的结果
Mov Disord. 2006 Aug;21(8):1221-5. doi: 10.1002/mds.20907.
10
[The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs].[纳瓦拉帕金森病患病率的估计。一项抗帕金森病药物消费的流行病学研究]
Rev Esp Salud Publica. 1995 Nov-Dec;69(6):479-85.

引用本文的文献

1
A population based study to analyse amyotrophic lateral sclerosis as a multi-step process.一项基于人群的研究,旨在分析肌萎缩侧索硬化症作为一个多步骤过程。
Sci Rep. 2025 Apr 1;15(1):11189. doi: 10.1038/s41598-025-89616-7.
2
Seasonality as a risk factor for deaths in Parkinson's disease.季节变化作为帕金森病死亡的一个风险因素。
Clinics (Sao Paulo). 2024 Oct 25;79:100506. doi: 10.1016/j.clinsp.2024.100506. eCollection 2024.
3
Circadian re-set repairs long-COVID in a prodromal Parkinson's parallel: a case series.昼夜节律重置修复长新冠与前驱帕金森平行:一项病例系列研究。
J Med Case Rep. 2024 Oct 23;18(1):496. doi: 10.1186/s13256-024-04812-9.
4
Polychromatic Light Exposure as a Therapeutic in the Treatment and Management of Parkinson's Disease: A Controlled Exploratory Trial.多色光照射作为帕金森病治疗与管理的一种疗法:一项对照探索性试验。
Front Neurol. 2018 Sep 19;9:741. doi: 10.3389/fneur.2018.00741. eCollection 2018.
5
Circadian Dysregulation in Parkinson's Disease.帕金森病中的昼夜节律失调
Neurobiol Sleep Circadian Rhythms. 2017 Jan;2:53-58. doi: 10.1016/j.nbscr.2016.11.001. Epub 2016 Nov 12.
6
Spatial distribution of Parkinson's disease mortality in Spain, 1989-1998, as a guide for focused aetiological research or health-care intervention.西班牙 1989-1998 年帕金森病死亡率的空间分布,为有针对性的病因研究或医疗干预提供指导。
BMC Public Health. 2009 Dec 2;9:445. doi: 10.1186/1471-2458-9-445.
7
The prevalence of Parkinson's disease in Portugal. A population approach.葡萄牙帕金森病的患病率:一项基于人群的研究
Eur J Epidemiol. 1994 Dec;10(6):763-7. doi: 10.1007/BF01719295.
8
The epidemiology of primary degenerative dementia and related neurological disorders.
Eur Arch Psychiatry Clin Neurosci. 1991;240(4-5):223-33. doi: 10.1007/BF02189531.